Phase I study of safety, tolerability, and efficacy of tebentafusp using a step-up dosing regimen and expansion in patients with metastatic uveal melanoma

Authors

Richard D Carvajal, Columbia University
Paul Nathan, Mount Vernon Cancer Centre
Joseph J Sacco, University of Liverpool
Marlana Orloff, Thomas Jefferson University
Leonel F Hernandez-Aya, Washington University School of Medicine in St. Louis
Jessica Yang, Columbia University
Jason J Luke, University of Chicago
Marcus O Butler, Princess Margaret Cancer Centre
Sarah Stanhope, Immunocore
Laura Collins, Immunocore
Cheryl McAlpine, Immunocore
Chris Holland, Immunocore
Shaad E Abdullah, Immunocore
Takami Sato, Thomas Jefferson University

Journal

Journal of Clinical Oncology

Publication Date

6-10-2022

Volume

40

Issue

17

First Page

1939

Last Page

1948

Document Type

Open Access Publication

DOI

10.1200/JCO.21.01805

Rights and Permissions

Carvajal RD, Nathan P, Sacco JJ, Orloff M, Hernandez-Aya LF, Yang J, Luke JJ, Butler MO, Stanhope S, Collins L, McAlpine C, Holland C, Abdullah SE, Sato T. Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma. J Clin Oncol. 2022 Jun 10;40(17):1939-1948. doi: 10.1200/JCO.21.01805 Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/

Recommended Citation

Carvajal, Richard D; Nathan, Paul; Sacco, Joseph J; Orloff, Marlana; Hernandez-Aya, Leonel F; Yang, Jessica; Luke, Jason J; Butler, Marcus O; Stanhope, Sarah; Collins, Laura; McAlpine, Cheryl; Holland, Chris; Abdullah, Shaad E; and Sato, Takami, "Phase I study of safety, tolerability, and efficacy of tebentafusp using a step-up dosing regimen and expansion in patients with metastatic uveal melanoma." Journal of Clinical Oncology. 40, 17. 1939 - 1948. (2022).
https://digitalcommons.wustl.edu/open_access_pubs/12033